Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 4/20 | 0.58 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065657 | 0.84 | MLKL (0.51) | MLKLALPLMAPK1ALDH1A1IDO1 | |
| SCHEMBL11849342 | 0.82 | MLKL (0.51) | MLKLALPLMAPK1ALDH1A1IDO1 | |
| SCHEMBL4725067 | 0.81 | ALDH1A1 (0.54) | MLKLALPLMAPK1ALDH1A1IDO1 | |
| SCHEMBL6757229 | 0.78 | ALPL (0.56) | MLKLALPLMAPK1ALDH1A1IDO1 | |
| SCHEMBL14770678 | 0.78 | MLKL (0.56) | MLKLMAPK1ALDH1A1IDO1POLB | |
| SCHEMBL13368242 | 0.78 | HTT (0.39) | MLKLMAPK1KMT2A | |
| SCHEMBL12065254 | 0.77 | MEN1 (0.46) | MLKLALDH1A1KMT2A | |
| SCHEMBL12066065 | 0.76 | MLKL (0.43) | MLKLMAPK1POLBKMT2AGAA | |
| SCHEMBL12065650 | 0.76 | MLKL (0.43) | MLKLALDH1A1IDO1POLBTAAR1 | |
| SCHEMBL13182507 | 0.75 | MLKL (0.52) | MLKLALPLMAPK1ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-9034872-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2015-05-19 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. | 2014-04-17 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2013-03-21 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | MLKL 4160/4885ALPL 3119/4885MAPK1 3326/4885 |
| US-20140107128-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | MLKL 2137/4885ALPL 2666/4885MAPK1 3645/4885 |
| US-20130072479-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | PDE5A, PDE3B, PDE3A | MLKL 4160/4885ALPL 3119/4885MAPK1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.